Business
RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome
RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.
About this update from Alexandria Real Estate Equities, Inc.
[{"type":"text","content":"Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.","length":472,"tagName":"p"},{"type":"image","alt":"RyboDyn logo: targeting the dark proteome (PRNewsfoto/RyboDyn)","displaySize":"","headline":null,"caption":"RyboDyn logo: targeting the dark proteome (PRNewsfoto/RyboDyn)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":79,"url":"https://media.zenfs.com/en/prnewswire.com/c2f03996730f5dc92ed1f01678e3c7ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cQ_lo4Jro5YNuDYicgkKDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c2f03996730f5dc92ed1f01678e3c7ff","width":400,"height":79}},"href":"https://mma.prnewswire.com/media/2594100/RyboDyn_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"RyboDyn has rapidly gained momentum following its discovery of a cryptic proteome—a previously uncharacterized layer of protein-coding potential derived from overlooked RNA species. Through its proprietary sequencing and AI-driven platform, RyboCypher™, the company has uncovered a new class of therapeutic targets that are cancer-specific, abundantly expressed on the cell surface, and absent in healthy tissues. In collaboration with Moffitt Cancer Center, RyboDyn recently demonstrated that several of these Dark Targets™ are conserved across patients, supporting their potential as the foundation for first-in-class precision immunotherapies.","length":651,"tagName":"p","attribs":{}},{"type":"text","content":""We're thrilled to join the LGL community and collaborate with peers who share our urgency to translate high-impact science," said Imad Ajjawi, PhD, MBA, CEO and Co-founder of RyboDyn. "Lilly's support comes at a pivotal moment...